Table 1.
Characteristics of the 57 included studies.
| Study | Design (Phase) | Diagnosis | Drug/Target | Total number of patients (M/F) | Dose (mg/kg) | mode of administration | Identifier |
|---|---|---|---|---|---|---|---|
| Blauvelt A 2021 (15) | III | PSO | Ixekizumab/IL-17A | 1346 (N/A) | 80 | i.h. | NCT01646177 |
| Reich K 2019 (16) | III | PSO | Secukinumab/IL-17A | 514 (342/172) | 300 | i.h. | NCT03090100 |
| Mease PJ 2020 (17) | IIIb/IV | PSA | Ixekizumab/IL-17A | 566 (312/254) | 80 | i.h. | NCT03151551 |
| Smolen JS 2020 (18) | IIIb/IV | PSA | Ixekizumab/IL-17A | 566 (312/254) | 80 | i.h. | NCT03151551 |
| Mrowietz U 2019 (19) | IIIb | PSO | Secukinumab/IL-17A | 237 (51/186) | 300; 150 | i.h. | NCT02008890 |
| Chandran V 2020 (20) | III | PSA | Ixekizumab/IL-17A | 386 (N/A) | 80 | N/A | NCT01695239 |
| Gelfand JM 2020 (21) | III | PSO | Secukinumab/IL-17A | 91 (61/30) | 300 | i.h. | NCT02690701 |
| Mease PJ 2017 (22) | III | PSA | Ixekizumab/IL-17A | 417 (192/225) | 80 | i.h. | NCT01695239 |
| McInnes IB 2017 (23) | N/A | PSA | Secukinumab/IL-17A | 299 (N/A) | 300; 150; 75 | N/A | NCT01752634 |
| Bagel J 2017 (24) | IIIb | PSO | Secukinumab/IL-17A | 102 (N/A) | 300 | i.h. | NCT02267135 |
| van der Heijde D 2018 (25) | III | PSA | Ixekizumab/IL-17A | 191 (80/111) | 80 | i.h. | NCT01695239 |
| Okubo Y 2019 (26) | N/A | PSO | Secukinumab/IL-17A | 13 (9/4) | 300 | N/A | NCT01406938 |
| Imafuku S 2017 (27) | III | PSO | Ixekizumab/IL-17A | 1296 (N/A) | 80 | N/A | NCT01474512 |
| Paul C 2015 (28) | III | PSO | Secukinumab/IL-17A | 182 (125/57) | 300; 150 | i.h. | NCT01636687 |
| Blauvelt A 2017 (29) | III | PSO | Ixekizumab/IL-17A | 771 (512/259) | 80 | N/A | NCT01646177 |
| Reich K 2020 (30) | IIIb | PSO | Ixekizumab/IL-17A | 54 (42/12) | 80 | i.h. | NCT02634801 |
| Wu NL 2017 (31) | III | PSO | Secukinumab/IL-17A | 51 (41/10) | 300; 150 | i.h. | N/A |
| Gottlieb A 2017 (32) | IIIb | PSO | Secukinumab/IL-17A | 205 (112/93) | 300; 150 | i.h. | NCT01806597 |
| Paul C 2019 (33) | IIIb | PSO | Ixekizumab/IL-17A | 136 (90/46) | 80 | i.h. | NCT02561806 |
| Ohtsuki M 2014 (34) | III | PSO | Secukinumab/IL-17A | 58 (49/9) | 300; 150 | i.h. | NCT01365455 |
| Valenzuela F 2017 (35) | III | PSO | Ixekizumab/IL-17A | 1604 (1061/543) | 80 | N/A | NCT01646177 |
| LeoNardi C 2018 (36) | III | PSO | Ixekizumab/IL-17A | 1346 (N/A) | 80 | i.h. | NCT01646177 |
| Reich K 2017 (37) | IIIb | PSO | Ixekizumab/IL-17A | 302 (202/100) | 80 | i.h. | NCT02561806 |
| Sticherling M 2017 (38) | N/A | PSO | Secukinumab/IL-17A | 200 (124/76) | 150 | i.h. | NCT02474082 |
| Blauvelt A 2017 (39) | III | PSO | Ixekizumab/IL-17A | 1226 (N/A) | 80 | i.h. | NCT01474512; NCT01597245 |
| Warren RB 2020 (40) | III | PSO | Secukinumab/IL-17A | 327 (213/114) | 300 | i.h. | NCT03478787 |
| Mease PJ 2018 (41) | II | PSA | ABT-122/IL-17A | 240 (121/119) | 240; 120 | i.h. | NCT02349451 |
| Genovese MC 2018 (42) | III | PSA | Ixekizumab/IL-17A | 310 (146/164) | 80 | i.h. | NCT02349295 |
| Körber A 2018 (43) | III | PSO | Secukinumab/IL-17A | 906 (407/498) | 300 | i.h. | NCT01365455; NCT01358578; NCT02074982 |
| Griffiths CE 2015 (44) | III | PSO | Ixekizumab/IL-17A | 2562 (1739/823) | 80 | i.h. | NCT01597245; NCT01646177 |
| Richard G 2014 (45) | III | PSO | Secukinumab/IL-17A | 2044 (1438/606) | 300; 150 | i.h. | NCT01365455; NCT01358578 |
| Kenneth B 2014 (46) | II | PSO | Ixekizumab/IL-17A | 129 (N/A) | 10; 25; 75; 150 | i.h. | NCT01107457 |
| Blauvelt A 2021 (47) | IV | PSO | Ixekizumab/IL-17A | 1025 (N/A) | 80 | i.h. | NCT03573323 |
| Rich P 2013 (48) | II | PSO | Secukinumab/IL-17A | 404 (306/98) | 150 | i.h. | NCT00941031 |
| Gordon KB 2016 (49) | III | PSO | Ixekizumab/IL-17A | 3866 (2622/1244) | 80 | i.h. | NCT01474512; NCT01597245; NCT01646177 |
| Bagel J 2021 (50) | IIIb | PSO | Secukinumab/IL-17A | 1102 (N/A) | 300 | i.h. | NCT02826603 |
| Lebwohl MG 2020 (51) | N/A | PSO | Ixekizumab/IL-17A | 1274 (N/A) | 80 | N/A | NCT01646177 |
| Stebut EV 2019 (52) | N/A | PSO | Secukinumab/IL-17A | 151 (102/49) | 300; 150 | N/A | N/A |
| Leonardi C 2020 (53) | III | PSO | Ixekizumab/IL-17A | 206 (140/66) | 80 | N/A | NCT01597245 |
| Thaci D 2015 (54) | IIIb | PSO | Secukinumab/IL-17A | 676 (481/195) | 300 | i.h. | NCT02074982 |
| Nash P 2017 (55) | III | PSA | Ixekizumab/IL-17A | 363 (169/194) | 80 | i.h. | NCT02349295 |
| Mease P 2017 (56) | III | PSA | Secukinumab/IL-17A | 996 (500/496) | 300; 150 | i.h. | NCT02404350 |
| D’Agostino MA 2021 (57) | III | PSA | Secukinumab/IL-17A | 166 (75/91) | 300; 150 | i.h. | NCT02662985 |
| McInnes IB 2020 (58) | III | PSA | Secukinumab/IL-17A | 397 (N/A) | 150 | i.h. | NCT01752634 |
| Mease PJ 2020 (59) | III | PSA | Brodalumab/IL-17R | 962 (483/479) | 140 | i.h. | NCT02029495; NCT02024646 |
| Seo SJ 2020 (60) | III | PSO | Brodalumab/IL-17R | 62 (38/24) | 210 | i.h. | NCT02982005 |
| Nakagawa H 2015 (61) | II | PSO | Brodalumab/IL-17R | 151 (120/31) | 70; 140; 210 | i.h. | N/A |
| Papp KA 2012 (62) | II | PSO | Brodalumab/IL-17R | 198 (127/71) | 70; 140; 210; 280 | i.h. | NCT00975637 |
| Pinter A 2021 (63) | IV | PSO | Brodalumab/IL-17R | 210 (145/65) | 210 | i.h. | NCT03331835 |
| Reich K 2021 (64) | III | PSO | Bimekizumab/IL-17A/F | 567 (406/161) | 320 | i.h. | NCT03370133 |
| Gordon KB 2021 (65) | III | PSO | Bimekizumab/IL-17A/F | 435 (313/122) | 320 | i.h. | NCT03410992 |
| Papp KA 2018 (66) | IIb | PSO | Bimekizumab/IL-17A/F | 250 (163/87) | 64; 160; 320; 480 | i.h. | NCT02905006 |
| Glatt S 2018 (67) | Ib | PSA | Bimekizumab/IL-17A/F | 53 (26/27) | 40; 80; 160; 320; 560 | i.v. | NCT02141763 |
| Blauvelt A 2020 (68) | IIb | PSA | Bimekizumab/IL-17A/F | 170 (N/A) | 64; 160; 320 | N/A | NCT03010527 |
| Glatt S 2018 (69) | I | PSO | Bimekizumab/IL-17A/F | 39 (30/9) | 8; 40; 160; 480; 640 | i.v. | NCT02529956 |
| Svecova D 2019 (70) | I | PSO | M1095/IL-17A/F | 41 (35/6) | 30; 60; 120; 240 | i.h. | NCT02156466 |
PSO, psoriasis; PSA, psoriatic arthritis; UC, ulcerative colitis; N/A, not available; M/F, Male/Female; i.v., intravenous injection; i.h., hypodermic injection.